Medicare's new ACCESS payment model opens a direct funding pathway for AI health monitoring tools that operate outside traditional clinical visits. The Centers for Medicare and Medicaid Services designed the model to reimburse artificial intelligence systems that perform continuous patient surveillance, medication adherence checks, housing coordination, and inter-visit care management.
Before ACCESS, no billable healthcare code existed for these AI-driven interventions. Startups building remote monitoring software, medication reminder systems, or social determinants-of-health platforms had no way to capture payment from the largest U.S. health insurer. The lack of reimbursement created a fundamental business problem. Hospitals and health systems couldn't justify purchasing AI tools without a revenue stream to offset costs. Venture-backed companies building these solutions faced uphill adoption battles despite strong clinical logic.
ACCESS changes the economics. The model establishes reimbursement rates for AI agents that work between clinical encounters. This includes systems that monitor chronic disease progression, flag patient deterioration, arrange community resources like housing assistance, and ensure medication compliance. The mechanism operates independently of traditional face-to-face visits, creating a new revenue bucket for healthcare AI vendors.
The move reflects CMS's recognition that AI can deliver preventive and care coordination value at scale. It also signals confidence in algorithmic safety and effectiveness for remote monitoring. However, most healthcare AI startups appear unaware of the opportunity. Limited venture funding has flowed toward companies positioned to capture ACCESS reimbursement.
The timing matters. Healthcare systems are building their AI infrastructure now, and those that understand ACCESS can design tools specifically for Medicare reimbursement. Startups that ignore the model risk building products optimized for self-pay or narrow commercial insurance channels, missing the largest payer in the U.S.
For venture investors, ACCESS represents a rare instance of regulatory tailwind. Payers typically resist new billing codes. CMS moving proact